A Next‐Generation ELISA for the Detection of Anti‐(Para)Nodal Antibodies in Autoimmune Nodopathy and COVID ‐19 Vaccinated Individuals

Key Points

• Evaluate a novel ELISA platform for detecting anti-(para)nodal antibodies in vaccinated individuals.
• Utilized a highly automated testing platform
• Conducted assessments of anti-(para)nodal antibodies
• Analyzed antibody frequency in COVID-19 vaccinated individuals
• Detected low frequency of anti-(para)nodal antibodies
• No clinical manifestations of autoimmune nodopathy observed in vaccinated individuals
• Confirmed vaccination safety regarding autoimmune nodopathy development.